These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21351205)

  • 21. Thrombophilic polymorphisms - factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T - in Tunisian patients with cerebral venous thrombosis.
    Ben Salem-Berrabah O; Fekih-Mrissa N; N'siri B; Ben Hamida A; Benammar-Elgaaied A; Gritli N; Mrissa R
    J Clin Neurosci; 2012 Sep; 19(9):1326-7. PubMed ID: 22721898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical impact of MTHFR polymorphism on the vascular complications of sickle cell disease.
    Moreira Neto F; Lourenço DM; Noguti MA; Morelli VM; Gil IC; Beltrão AC; Figueiredo MS
    Braz J Med Biol Res; 2006 Oct; 39(10):1291-5. PubMed ID: 16906320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of inherited thrombophilia on the risk of recurrent venous thromboembolism onset in Georgian population.
    Pirtskhelani N; Kochiashvili N; Makhaldiani L; Pargalava N; Gaprindashvili E; Kartvelishvili K
    Georgian Med News; 2014 Feb; (227):93-7. PubMed ID: 24632656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.
    Kim RJ; Becker RC
    Am Heart J; 2003 Dec; 146(6):948-57. PubMed ID: 14660985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.
    Simone B; De Stefano V; Leoncini E; Zacho J; Martinelli I; Emmerich J; Rossi E; Folsom AR; Almawi WY; Scarabin PY; den Heijer M; Cushman M; Penco S; Vaya A; Angchaisuksiri P; Okumus G; Gemmati D; Cima S; Akar N; Oguzulgen KI; Ducros V; Lichy C; Fernandez-Miranda C; Szczeklik A; Nieto JA; Torres JD; Le Cam-Duchez V; Ivanov P; Cantu-Brito C; Shmeleva VM; Stegnar M; Ogunyemi D; Eid SS; Nicolotti N; De Feo E; Ricciardi W; Boccia S
    Eur J Epidemiol; 2013 Aug; 28(8):621-47. PubMed ID: 23900608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombophilic Mutations Among Patients with Sickle Cell Disease.
    Nefissi RB; Ouali F; Massaoud T; Gritli N
    Clin Lab; 2017 Nov; 63(11):1815-1818. PubMed ID: 29226645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of three prothrombotic polymorphisms among Syrian population: factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase C677T.
    Jarjour RA; Ammar S; Majdalawi R
    Ann Hum Biol; 2017 Feb; 44(1):70-73. PubMed ID: 26560857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients.
    Dölek B; Eraslan S; Eroğlu S; Kesim BE; Ulutin T; Yalçiner A; Laleli YR; Gözükirmizi N
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):435-8. PubMed ID: 17911197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion.
    Cruciani F; Moramarco A; Curto T; Labate A; Recupero V; Conti L; Gandolfo GM; Balacco Gabrieli C
    Clin Ter; 2003; 154(5):299-303. PubMed ID: 14994919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of thrombotic risk factors in end-stage renal disease.
    Tripathi G; Sankhwar SN; Sharma RK; Baburaj VP; Agrawal S
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):132-40. PubMed ID: 19520684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR.
    Hessner MJ; Luhm RA; Pearson SL; Endean DJ; Friedman KD; Montgomery RR
    Thromb Haemost; 1999 May; 81(5):733-8. PubMed ID: 10365746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor V Leiden (G1691A), the prothrombin 3'-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): a single genetic test genotypes all three loci--determination of frequencies in the S. Wales population of the UK.
    Bowen DJ; Bowley S; John M; Collins PW
    Thromb Haemost; 1998 May; 79(5):949-54. PubMed ID: 9609227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombophilic genes alterations as risk factor for recurrent pregnancy loss.
    Farahmand K; Totonchi M; Hashemi M; Reyhani Sabet F; Kalantari H; Gourabi H; Mohseni Meybodi A
    J Matern Fetal Neonatal Med; 2016; 29(8):1269-73. PubMed ID: 26135458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.
    Falvella FS; Cremolini C; Miceli R; Nichetti F; Cheli S; Antoniotti C; Infante G; Martinetti A; Marmorino F; Sottotetti E; Berenato R; Caporale M; Colombo A; de Braud F; Di Bartolomeo M; Clementi E; Loupakis F; Pietrantonio F
    Pharmacogenomics J; 2017 Jul; 17(4):331-336. PubMed ID: 27001121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [C677T mutation in methylentetrahydrofolatereductase gene in patients with venous thromboses from the central region of Russia correlates with a high risk of pulmonary artery thromboembolism].
    Avdonin PV; Kirienko AI; Kozhevnikova LM; Shostak NA; Babadaeva NM; Leont'ev SG; Petukhov EB; Kubatiev AA; Savel'ev VS
    Ter Arkh; 2006; 78(6):70-6. PubMed ID: 16881367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylenetetrahydrofolate reductase C677T genotype and venous thromboembolic disease.
    Couturaud F; Oger E; Abalain JH; Chenu E; Guias B; Floch HH; Mercier B; Mottier D; Leroyer C
    Respiration; 2000; 67(6):657-61. PubMed ID: 11124649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Screening for pre-eclampsia in a low-risk population at 24 weeks: uterine artery Doppler flow velocimetry and genetic variants of factor V, prothrombin and methylenetetrahydrofolate reductase].
    Driul L; Damante G; D'Elia A; Springolo F; Ianni A; Di Leonardo C; Angelini M; Marchesoni D
    Minerva Ginecol; 2004 Oct; 56(5):385-90. PubMed ID: 15531855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of factor V Leiden, Janus kinase 2, prothrombin, and MTHFR mutations with primary Budd-Chiari syndrome in Egyptian patients.
    El Sebay HM; Safan MA; Daoud AA; Tayel SI; Nouh MA; El Shafie S
    J Gastroenterol Hepatol; 2016 Jan; 31(1):235-40. PubMed ID: 26238013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.